MarginsXMarginsX
Home › Markets › Health Care › BDRX

Biodexa Pharmaceuticals plc American Depositary Shs (BDRX)

BDRX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.24
-6.28% on the day
Market cap
$1.2M
Nano cap
Revenue
No annual revenue filed since the period ending 2023-12-31
Net income
No annual revenue filed since the period ending 2023-12-31

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerBDRX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited Kingdom
IPO yearNot reported by the screener
SEC CIK0001643918
SEC industry codePharmaceutical Preparations
Incorporated inUnited Kingdom

Financials

No annual revenue filed since the period ending 2023-12-31.

Warning signs

Cash runway
18.3 months
$11.3M cash at December 31, 2025
Share count, 1 year
+3277.5%
2024-12-31 to 2025-12-31
Going-concern doubt
Yes
20-F filed March 27, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions raise substantial doubt about the Group's ability to continue as a going concern."
20-F 2026-03-27
Cash and burn$11.3M cash; operating cash flow -$1.8M a quarter.Report 2025-12-31
Shares outstandingNo cover-page share count in XBRLCover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 1 424B5 takedownsLatest 2026-07-01
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPKF Littlejohn LLP, London, United KingdomPCAOB Form AP 2026-04-15
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
Not filed-$8.4M-$7.4M$11.3M$81KNeeds four quarters20-F 2026-03-27

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
333-279994
424B32026-10-14
Latest annual report20-F2026-03-27
Latest quarterly / interim
FORM 6-K
6-K2026-11-09

Source: SEC EDGAR submissions feed, 732 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-3.2%
1 month-14.3%
3 months-80.8%
Year to date-97.4%
1 year-98.8%
From 52-week high-99.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
GOVXGeoVax Labs Inc.$2.02+18.48%$1.1M
ELABPMGC Holdings Inc.$1.66+5.06%$1.3M
KAPAKairos Pharma Ltd.$0.4069-10.30%$1.4M
APVOAptevo Therapeutics Inc.$0.5486-7.66%$1.5M
MTNBMatinas Biopharma Holdings Inc.$0.9270+3.00%$908K
OGENOragenics Inc.$0.1980-1.49%$893K
ARTLArtelo Biosciences Inc.$1.70-17.87%$1.6M
SPRCSciSparc Ltd.$0.3307-10.62%$815K

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier